<DOC>
	<DOC>NCT00131742</DOC>
	<brief_summary>This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.</brief_summary>
	<brief_title>Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented clinical history compatible with chronic hepatitis B infection Other protocoldefined inclusion criteria may apply Patient is pregnant or breastfeeding Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV Patient has previously received lamivudine or any investigational antiHBV nucleoside or nucleotide analog Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>